Lexicon Pharmaceuticals (LXRX) Stock Forecast: StockMap's 2-Week Call
LXRX stock forecast: StockMap's model leans Underperform on Lexicon Pharmaceuticals for the two weeks after the Nov 19 close, toward LXRX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on LXRX since Sep 30; by chance, a call on the same dates was right 46% of the time.
Lexicon Pharmaceuticals last closed at $1.67, -2.91% on the session.
Against the IVW growth benchmark the position is -0.58% over the forecast window.
Lexicon Pharmaceuticals' market cap is $743.52M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -36 (too close to call).
Where LXRX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
27 daily calls for LXRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Lexicon Pharmaceuticals in the 20th percentile on return on equity, where 100 is best.
Lexicon Pharmaceuticals is classified under Health Care / Pharmaceuticals.
StockMap tracks Lexicon Pharmaceuticals as the 67th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Lexicon Pharmaceuticals ranks 82nd of 153 in the group, against a group median of -0.36.